- Recruiting
NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies - RRMM Myeloma
NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies
NCT04068597: Phase 1/2: Study to Evaluate CCS1477 in Haematological Malignancies
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Sponsor
ClinicalTrials.gov Identifier: NCT04068597
Official Title: An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
First Posted: August 28, 2019
Click here for details on Clinicaltrials.gov
Inobrodib (Code C160195)
CCS 1477
CCS-1477
CCS1477
INOBRODIB
Inobrodib
p300 HAT/CREB Binding Protein Inhibitor CCS1477
p300/CBP Bromodomain Inhibitor CCS1477
Drug: CCS1477
Drug: Pomalidomide
Drug: Dexamethasone
Locations
United States, Arizona
Europe
France
Spain
Sweden
United Kingdom